Regulation of mTOR Activity

Regulation of mTOR by RTK-PI-3K

Several reports indicate that insulin [104-106] induces a modest (~ twofold) increase in the activity of immuno-precipitated mTOR; a more robust increase in mTOR activity is observed in response to neurotrophin (CNTF, BDNF) treatment of primary neurons and cell lines [107,108]. Overexpression of active forms of PI-3K or PKB results in increased 4E-BP phosphorylation at the rapamycin-/ wortmannin-sensitive sites [109] and activation of p70 S6K [110], although PKB itself does not phosphorylate either 4E-BP or p70 S6K. Whether the effects of insulin, neurotrophins, recombinant PI-3K, and PKB reflect a direct modification and activation of TOR kinase or more indirect mechanisms (e.g., phosphorylation of and disinhibition from TSC [79], PDK1 and/or PKB recruitment of other 4E-BP and/or p70 S6K kinases, negative regulation of protein phosphatase, or some combination of these actions) is not known. In addition to the modest (twofold) increase in the activity of immunoprecipitated mTOR, activation of PKB in vivo is associated with increased phosphorylation of mTOR at Ser2448 [106,111], a canonical PKB site. The functional significance of PKB-catalyzed mTOR phosphorylation is unclear, as mutation of Ser2448 to Ala on the rapamycin-resistant mTOR (Ser2035 Thr) does not alter its ability to rescue 4E-BP or p70 S6K from rapamycin-induced dephosphorylation [106]. Nevertheless, deletion of the mTOR segment surrounding Ser2448 [106] or the binding of a polyclonal Ab [66,105] to this site each increase the in vitro mTOR kinase activity by five- to tenfold, suggesting that a regulatory input (e.g., TSC inhibition) whose mechanism remains to be elucidated may be effected through this segment of mTOR.

Microinjection of a prokaryotic recombinant FRB fragment into MG63 osteosarcoma cells, a cell line whose growth is reliably arrested in G: by rapamycin, prevents entry into S [112], suggesting that the function of the FRB domain in maintaining TOR activity might be regulatory rather than structural. An important insight into the function of the FRB domain was the finding that this segment binds selectively to lipid vesicles that contain phosphatidic acid (PA) [113]. This binding can be inhibited by addition of an FKBP12/rapamycin complex or partially by mutation of mTOR Arg2109 to Ala; introduction of this mutation into a rapamycin-resistant mTOR (S2035T) mutant reduces by approximately 40% its ability to rescue coexpressed p70S6K from rapamycin inhibition. PA added exogenously can activate p70 S6K and 4E-BP phosphorylation. Mitogens, though activation of PLD, increase cellular PA levels, and butanol, which sequesters intracellular PA as an ester, inhibits the serum-induced activation of p70 S6K and the phosphorylation of 4E-BP without affecting phosphorylation of PKB or MAPK. Moreover, a mutant of p70 S6K resistant to inhibition by rapamycin (see above) is also resistant to inhibition by butanol. The noncovalent interaction of PA with the mTOR FRB domain appears to provide one component of the mitogen activation of mTOR signaling.

Figure 2

In summary, mTOR kinase activity is regulated in mammalian cells by tyrosine-kinase-linked receptors through a PI-3K-PDK1-Akt pathway, at least in some cell backgrounds and possibly for some, but not all, substrates. This activation persists to some degree after extraction and immunoprecipitation and is probably attributable to PI-3K/PB-induced mTOR phosphorylation. An additional important site of PKB regulation is through the phosphory-lation of, and disinhibition from, TSC2 [79]. Moreover, as described above, an RTK-PLD-induced accumulation of phosphatidic acid [113] probably promotes mTOR activity through a noncovalent interaction; this activation is unlikely to survive cell extraction. An understanding of the TOR scaffold protein Raptor [70,71] as a site of regulation will be necessary for understanding the specific mechanisms that regulate the mTOR kinase activity toward each of its physiologic substrates. Finally, the role of gephyrin [114] in the receptor regulation of mTOR remains unclear. Gephyrin is a ubiquitously expressed tubulin-binding protein necessary for the postsynaptic clustering of glycine receptors in neurons. Gephrin binds to mTOR (AA1010-1128). Mutations in this region that abolish mTOR interactions with gephyrin abrogate the ability of a rapamycin-resistant mTOR (Ser2035Thr) to rescue p70 S6K and 4E-BP from rapamycin-induced dephosphorylation.

Regulation of mTOR by Amino Acids

The evidence that TOR retains its role as a nutrient-sensor in metazoans is entirely indirect; in contrast to the generally reproducible, if modest, stimulatory effects of insulin and neurotrophins, there has been no demonstration that alterations in the nutrient environment cause stable changes in mTOR kinase activity that can be measured by mTOR kinase assay in vitro, although it is reported that nutrient deprivation promotes an inhibitory interaction between Raptor and mTOR [70,71]. Nevertheless, there is persuasive evidence that TOR kinase activity in vivo is controlled by inputs related to amino acid and overall energy sufficiency. Thus, in a wide range of cultured mammalian cells, withdrawal of medium amino acids leads to progressive deacti-vation of the p70 S6K and dephosphorylation of eIF 4E-BP over 1 to 2 hours and completely inhibits the ability of insulin to promote these phosphorylations [87,115-117]. Amino acid withdrawal, however, does not significantly affect, at least over this initial interval, the upstream elements of the insulin signaling pathway (i.e., IR/IRS tyrosine phosphorylation, PI-3K activity, PKB or MAPK activation). Readdition of amino acids restores phosphorylation of p70 S6K on 4E-BP and their responsiveness to insulin. Moreover, elevation of ambient concentration of amino acids to higher than usual levels causes a progressive increase in p70 S6K activity and 4E-BP phosphorylation to levels observed with maximal insulin stimulation; at these high amino acid concentrations, addition of insulin gives no further stimulation of p70 S6K activity [87]. Thus, amino acid deficiency, like rapamycin, results in the selective dephosphorylation of these two well characterized TOR targets in a manner that overrides the activating input of the RTK/PI-3K pathway. Notably, the doubly deleted rapamycin-resistant p70 S6K mutant, p70A2-46/ACT104, is also highly resistant to deactivation/dephosphorylation by amino acid withdrawal [87]. This finding establishes that amino acid withdrawal, like rapamycin, does not inhibit any of the steps necessary for the insulin/PI-3K phosphorylation of p70 S6K Thr252 (the PDK1 site) and Thr412 (unknown kinase), but rather promotes the dephosphorylation of these sites; mTOR and amino acid sufficiency thus appear to inhibit the same p70 S6K phosphatase. Although rapamycin inhibits the ability of amino acid readdition to restore p70 S6K phosphorylation, it has not been formally established whether amino acids require mTOR to inhibit this putative p70 S6K phosphatase. Wortmannin also inhibits amino-acid-induced p70 S6K phosphorylation, but concentrations higher than those sufficient to inhibit type 1a PI-3K are required [39] and correspond to those necessary for inhibition of mTOR itself [118]. Subsequent work demonstrated that the rapamycin-sensitive phosphorylation sites in the nPKCs (5 and e) are also dephosphorylated in response to amino acid withdrawal [100,101].

The complete restoration of p70 S6K and 4E-BP phos-phorylation in cell culture requires the readdition of all 20 amino acids; readdition of single amino acids is without effect, except for leucine, which enables a variable extent of partial restoration in many cell lines [39,88,115,119]. Similarly, whereas removal of any single amino acid usually results in some dephosphorylation, the most substantial inhibition is observed on removal of leucine and occasionally arginine. A large body of in vivo experiments by Jefferson et al. [120-123] indicate that leucine exerts significant stimulatory action on the phosphorylation of p70 S6K and 4E-BP and is uniquely effective in promoting the synthesis of ribosomal proteins, providing strong evidence that the amino-acid-activated, mTOR-dependent pathways evident in cell culture are operative in vivo and are one component of the multiple mechanisms by which amino acids and insulin coordinately regulate protein synthesis especially in skeletal muscle.

Although evidence has been provided for the existence of a membrane-localized leucine receptor, at least in regard to amino-acid-regulation of autophagy in hepatocytes [124], it is likely that the majority of amino-acid-dependent responses mediated by mTOR are initiated at an intracellu-lar site [119]. Thus, inhibition of mRNA translation, either at the level of initiation (anisomycin) [125] or elongation (cycloheximide) [126], results in the activation of p70 S6K and hyperphosphorylation of 4E-BP [127] in a rapamycin-sensitive manner. Reciprocally, overexpression of eIF-4E (although transforming in many cell backgrounds) is accompanied by hypophosphorylation of 4E-BP and p70 S6K [127]. An attractive hypothesis is that the ability of protein synthesis inhibitors to stimulate the phosphorylation of p70 S6K and 4E-BP might reflect the activation of mTOR, induced by the accumulation of some intermediate in the translational process (e.g., a minor acylated tRNA) or by a byproduct of stalled translation, analogous to the synthesis of guanosine tetraphosphate during the "stringent" response in bacteria [128]. Support for such a mechanism is provided by the observation that amino acid alcohols, which inhibit cognate tRNA synthetase activity and protein synthesis, nevertheless cause dephosphorylation of 4E-BP and p70 S6K (suggesting a decrease in mTOR activity), in contrast to anisomycin [129]. Moreover, cycloheximide overcomes the dephosphorylation of p70 S6K/4E-BP caused by amino acid withdrawal. Similarly, CHO cells bearing a temperature-sensitive mutant histidyl tRNA synthetase, when shifted to the nonpermissive temperature, exhibit dephosphorylation of 4E-BP and p70 S6K [129]. If mTOR is regulated by the charging of tRNAs, this is accomplished through a mechanism distinct from that regulating the GCN2 kinase [130], as well as that underlying the bacterial stringent response [131].

Regulation of mTOR by Energy Sufficiency

Although the phosphorylation of 4E-BP is suppressed by amino acid withdrawal, some degree of insulin-stimulated 4E-BP phosphorylation persists under these conditions, to a degree sufficient to displace 4E-BP from 4E and to promote an increased association of eIF-4E with eIF-4G [132]. In CHO cells deprived of both amino acids and glucose, the basal- and insulin-stimulated phosphorylation of Thr 36/45 is severely inhibited; readdition of glucose alone, although insufficient to enable detectable phosphorylation of p70 S6K1 Thr412 or Ser444/447, allows substantial insulin-stimulated Thr36/45 phosphorylation and significant basal and insulin stimulated protein synthesis. This effect of glucose requires its metabolism and can be reproduced in part by lactate [132]. Although the identity of the kinase responsible for the glucose-dependent, insulin-stimulated phos-phorylation of 4E-BP Thr36/45 is not known, a plausible candidate is mTOR, inasmuch as these are the primary sites of mTOR-catalyzed 4E-BP phosphorylation. The dependence of this response on glucose metabolism suggests that mTOR kinase activity is itself, to some extent, dependent on and regulated by some product of glucose metabolism, independent of amino acid sufficiency, PI-3K, and PKB. Several observations indicate that this input is related to the state of overall energy sufficiency, as reflected by the concentration of adenine nucleotides. Thus, inhibitors of glycosis such as 2-deoxyglucose (2DG) and inhibitors of mitochondr-ial oxidative phosphorylation, e.g., rotenone or CN- both cause a marked inhibition of 4E-BP1 and p70 S6K phospho-rylation, at concentrations that have little effect on PKB or MAPK activation [133]. Notably, a rapamycin-resistant mutant of p70 S6K previously shown to be resistant to inhibition on withdrawal of amino acids is also entirely resistant to the inhibitory effects of 2DG, strongly supporting the conclusion that the inhibitory effects of energy depletion on p70 S6K and presumably 4E-BP are mediated by inhibition of mTOR. It has been suggested that mTOR is directly sensing the concentration of ATP itself, based on the apparently high ED50 for ATP (~1.0 mM) in the mTOR-catalyzed phosphorylation of 4E-BP in vitro [132]. This estimate of Km for ATP, however, is probably compromised by the copurifica-tion with mTOR of protein phosphatases and other contaminants. A more plausible mediator of TOR inhibition in the setting of energy depletion is the AMP-activated kinase (AMPK) system [134,135]. AICAR, a precursor of the AMPK activator ZMP, can inhibit p70 S6K and 4E-BP phosphorylation in cell culture, at least in cells able to efficiently convert this precursor to ZMP, without inhibition of PKB and MAPK. In addition, mTOR directly and specifically associates with AMPK. AICAR given by subcutaneous injection to rats results in an inhibition in skeletal muscle of p70 S6K (Thr412) and 4E-BP (Thr37) phospho-rylation, accompanied by a decrease in the association of eIF-4E with eIF-4G and an inhibition of protein synthesis [135]. The effects of AICAR in skeletal muscle may also be mediated by an inhibition of the PI-3K pathway inasmuch as AICAR injection in vivo also results in decreased phosphorylation of PKB (Ser473) and mTOR Ser2448, a canonical site of PKB-catalyzed phosphorylation in vivo; the latter responses are not seen upon glucose withdrawal from cultured cells. In summary, mTOR output is regulated by the cellular energy state, although this appears to be secondary in importance to regulation by amino acid sufficiency. Inhibition of mTOR by AMPK is likely to contribute an important component of the energy-dependent regulation of TOR.


1. Schreiber, S. (1991). Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251, 283-287.

2. Dumont, F. J. and Su, G. (1995). Mechanism of action of the immunosuppressant rapamycin. Life Sci. 58, 373-395.

3. Abraham, R. T. and Wiederrecht, G. J. (1996). Immunopharmacology of rapamycin. Ann. Rev. Immunol. 14, 483-510.

4. Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., and Hall, M. N. (1993). Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73, 585-596.

5. Cafferkey, R., Young, P. R., McLaughlin, M. M., Bergsma, D. J., Koltin, Y., Sathe, G. M., Faucette, L., Eng, W. K., Johnson, R. K., and Livi, G. P. (1993). Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol. Cell Biol. 13, 6012-6023.

6. Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S., and Schreiber, S. L. (1994). A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756-758.

7. Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S. H. (1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35-43.

8. Chiu, M. I., Katz, H., and Berlin, V. (1994). RAPT1, a mammalian homolog of yeast TOR, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. USA 91, 12574-12578.

9. Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., and Abraham, R. T. (1995). Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270, 815-822.

10. Barbet, N. C., Schneider, U., Helliwell, S. B., Stansfield, I., Tuite, M. F., and Hall, M. N. (1996). TOR controls translation initiation and early G1 progression in yeast. Mol. Biol. Cell 7, 25-42.

11. Ohsumi, Y. (2001). Molecular dissection of autophagy: two ubiquitin-like systems. Nat. Rev. Mol. Cell Biol. 2, 211-216.

12. Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., and Schreiber, S. L. (1999). Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the TOR proteins. Proc. Natl. Acad. Sci. USA 96, 14866-14870.

13. Cardenas, M. E., Cutler, N. S., Lorenz, M. C., Di Como, C. J., and Heitman, J. (1999). The TOR signaling cascade regulates gene expression in response to nutrients. Genes Devel. 13, 3271-3279.

14. Shamji, A. F., Finny, G., Kuruvilla, G., and Schreiber, S. L. (2000). Partitioning the transcriptional program induced by rapamycin among the effectors of the TOR proteins. Curr. Biol. 10, 1574-1581.

15. Long., X., Spycher, C., Han, S. Z., Rose, A. M., Müller, F., and Avruch, J. (2002). TOR deficiency in C. elegans causes developmental arrest and intestinal atrophy by inhibition of mRNA translation. Curr. Biol. 12, 1448-1461.

16. Gingras, A.-C., Raught, B., and Sonenberg, N. (2001). Regulation of translational initiation by FRAP/mTOR. Genes Dev. 15, 807-826.

17. Fingar, D. C., Salama, S., Tsou, C., Harlow, E., and Blenis, J. (2002). Mammalian cell size is controlled by mTOR and its downstream targets S6K2 and 4EBP1/eIF4E. Genes Dev. 16, 1472-1487.

18. Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., and Glass, D. J. (2001). Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell. Biol. 3, 1009-1013.

19. Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., and Yancopoulos, G. D. (2001). Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3, 1014-1019.

20. Shioi, T., McMullen, J. R., Kang, P. M., Douglas, P. S., Obata, T., Franke, T. F., Cantley, L. C., and Izumo, S. (2002). Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22, 2799-2809.

21. Edinger, A. L. and Thompson, C. B. (2002). Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276-2288.

22. Montagne, J., Stewart, M. J., Stocker, H., Hafen, E., Kozma, S. C., and Thomas, G. (1999). Drosophila S6 kinase: a regulator of cell size. Science 285, 2126-2129.

23. de Groot, R. P., Ballou L. M., and Sassone-Corsi P. (1994). Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell 79, 81-91.

24. Wilson, K. F., Wu, W. J., and Cerione, R. A. (2000). Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex. J. Biol. Chem. 275, 37307-37310.

25. Wang, X., Li, W., Williams, M., Terada, N., Alessi, D. R., and Proud, C. G. (2001). Regulation of elongation factor 2 kinase by p90 (RSK1) and p70 S6 kinase. EMBO J. 20, 4370-4379.

26. Yeaman, S. J., Armstrong, J. L., Bonavaud, S. M., Poinasamy, D., Pickersgill, L., and Halse, R. (2001). Regulation of glycogen synthesis in human muscle cells. Biochem. Soc. Trans. 29 (pt. 4), 537-541.

27. Harada, H., Andersen, J. S., Mann, M., Terada, N., and Korsmeyer, S. J. (2001). p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. USA 98, 9666-9670.

28. Tang, H., Hornstein, E., Stolovich, M., Levy, G., Livingstone, M., Templeton, D., Avruch, J., and Meyuhas, O. (2001). Amino acid-induced translation of TOP mRNAs is fully dependent on phos-phatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol. Cell. Biol 21, 8671-8683.

29. Hu, C., Pang, S., Kong, X., Velleca, M., and Lawrence, Jr., J. C. (1994). Molecular cloning and tissue distribution of PHAS-I, an intracellular target for insulin and growth factors. Proc. Natl. Acad. Sci. USA 91, 3730-3734.

30. Pause. A., Belsham, G. J., Donze, O., Lin, T. A., Lawrence, J. C., and Sonenberg, N. (1994). Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 371, 762-767.

31. Lin, T. A., Kong, X., Haystead, T. A., Pause, A., Belsham, G., Sonenberg, N., and Lawrence, Jr., J. C. (1994). PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science 266, 653-656.

32. Lin, T. A., Kong, X., Saltiel, A. R., Blackshear, P. J., and Lawrence, Jr., J. C. (1995). Control of PHAS-I by insulin in 3T3-L1 adipocytes. Synthesis, degradation, and phosphorylation by a rapamycin-sensitive and mitogen-activated protein kinase-independent pathway. J. Biol. Chem. 270, 18531-18538.

33. von Manteuffel, S. R., Gingras, A.-C., Ming, X. F., Sonenberg, N., and Thomas, G. (1996). 4E-BP1 phosphorylation is mediated by the FRAP-p70 S6K pathway and is independent of mitogen-activated protein kinase. Proc. Natl. Acad. Sci. USA. 93, 4076-4080.

34. Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., and Schreiber, S. (1995). Control of the p70 kinase by kinase activity of FRAP in vivo. Nature 377, 441-446.

35. Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng , Q-P., Kasuga, M., Nishimoto, I., and Avruch, J. (1997). Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 272, 26457-26463.

36. Brunn, G. J., Hudson, C. C., Sekulic, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, Jr., J. C., and Abraham, R. T. (1997). Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99-101.

37. Meyuhas O. and Hornstein, E. (2000). Translational control of TOP mRNAs, in Sonenberg, N., Hershey, J. W. B., and Merrick, W. C., Eds., Translation Control of Gene Expression, p671-693. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

38. Blommaart, E. F. C., Luiken, J. J. F. P., Blommaart, P. J. E., van Woerkom, G. M., and Meijer, A. J. (1995). Phosphorylation of riboso-mal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J. Biol. Chem. 270, 2320-2326.

39. Shigemitsu, K., Tsujishita, Y., Hara, K., Nanahoshi, M., Avruch, J., and Yonezawa, K. (1999). Regulation of translational effectors by amino acid and mammalian target of rapamycin signaling pathways. Possible involvement of autophagy in cultured hepatoma cells. J. Biol. Chem. 274, 1058-1065.

40. Conlon, I. and Raff, M. (1999). Size control in animal development. Cell 96, 235-244.

41. Sherr, C. J. (2000). The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60, 3689-3695.

42. Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivieres, S., Mercep, L., and Ferrari, S. (1998). Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and proteinsta-bility. J. Biol. Chem. 273, 14424-14429.

43. Olashaw, N. and Pledger, W. J. (2002). Paradigms of growth control: relation to Cdk activation. Sci. STKe 134, RE7.

44. Dijkers, P. F., Medema, R. H., Pals, C., Banerji, L., Thomas, N. S., Lam, E. W., Burgering, B. M., Raaijmakers, J. A., Lammers, J. W., Koenderman, L., and Coffer, P. J. (2000). Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell. Biol. 20, 9138-9148.

45. Hengst, L. and Reed, S. I. (1996). Translational control of p27Kip1 accumulation during the cell cycle. Science 271, 1861-1864.

46. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. (1995). Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-685.

47. Sherr, C. J. and Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512.

48. Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M. H., Massague, J., Crabtree, G., and Roberts, J. (1994). Interleukin-2-mediated elimination of the p27 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372, 570-573.

49. Mamillapalli, R., Gavrilova, N., Mihaylova, V. T., Tsvetkov, L. M., Wu, H., Zhang, H., and Sun, H. (2001). PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol. 11, 263-267.

50. Tsukiyama, T., Ishida, N., Shirane, M., Minamishima, Y. A., Hatakeyama, S., Kitagawa, M., Nakayama, K., and Nakayama, K. (2001). Down-regulation of p27Kip1 expression is required for development and function of T cells. J. Immunol. 166, 304-312.

51. Marx, S. O. and Marks, A. R. (2001). Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104, 852-855.

52. Castedo, M., Ferri, K. F., and Kroemer, G. (2002). Mammalian target of rapamycin (mTOR): pro-andanti-apoptotic. Cell Death Diff. 9, 99-100.

53. Huang, S. and Houghton, P. J. (2002). Inhibitors of mammalian target of rapamycin as a novel antitumor agents: from bench to clinic. Curr. Opin. Invest. Drugs 3, 295-304.

54. Aoki, M., Blazek, E., and Vogt, P. K. (2000). A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA 98, 136-141.

55. Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., and Sawyers, C. L.

(2001). Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98, 10314-10319.

56. Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., Frost, P., Dreisbach, V., Blenis, J., Gaciong, Z., Fisher, P., Sawyers, C., Hedrick-Ellenson, L., and Parsons, R. (2001). An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA 98, 10320-10325.

57. Louro, I. D., McKie-Bell, P., Gosnell, H., Brindley, B. C., Bucy, R. P., and Ruppert, J. M. (1999). The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Cell Growth Differ. 10, 503-516.

58. Yakahashi, T., Hara, K., Inoue, H., Kawa, Y., Tokunaga, C., Hidayat, S., Yoshino, K., Kuroda, Y., and Yonezawa, K. (2000). Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes Cells 5, 765-767.

59. Choi, J., Chen, J., Schreiber, S. L., and Clardy, J. (1996). Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239-242.

60. Menand, B., Desnos, T., Nussaume, L., Berger, F., Bouchez, D., Meyer, C., and Robaglia, C. (2002). Expression and disruption of the Arabidopsis TOR (target of rapamycin) gene. Proc. Natl. Acad. Sci. USA. 99, 6422-6477.

61. Weisman, R. and Choder, M. (2001). The fission yeast TOR homolog, tor1+, is required for the response to starvation and other stresses via a conserved serine. J. Biol. Chem. 276, 7027-7032.

62. Groves, M. R., Hanlon, N., Turowski, P., Hemmings, B. A., and Barford, D. (1999). The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs. Cell 96, 99-110.

63. Kunz, J., Schneider, U., Howald, I., Schmidt, A., and Hall, M. N.

(2002). HEAT repeats mediate plasma membrane localization of Tor2p in yeast. J. Biol. Chem. 275, 37011-37020.

64. Kim, J. E. and Chen, J. (2000). Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc. Nat. Acad. Sci. USA 97, 14340-14345.

65. Brunn, G. J., Hudson, C. C., Sekulic, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, Jr., J. C., and Abraham, R. T. (1997). Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99-101.

66. Lawrence, Jr., J. C. and Brunn, G. J. (2001). Insulin signaling and the control of PHAS-1 phosphorylation. Prog. Mol. Subcell. Biol. 26, 1-31.

67. Gingras, A.-C., Raught, B., and Sonenberg, N. (2001). Control of translation by the target of rapamycin proteins. Prog. Mol. Subcell. Biol. 27, 143-174.

68. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. (1998). RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Nat. Acad. Sci USA 95, 1432-1437.

69. Isotani, S., Hara, K., Tokunaga, C., Inoue, H., Avruch, J., and Yonezawa, K. (1999). Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J. Biol. Chem. 274, 34493-34498.

70. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2002). mTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175.

71. Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., and Yonezawa, K. (2002). Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189.

72. Hengstschlager, M., Rodman, D. M., Miloloza, A., Hengstschlager-Ottnad, E., Rosner, M., and Kubista, M. (2001). Tuberous sclerosis gene products in proliferation control. Mutation Res. 488, 233-239.

73. Cheadle, J. P., Reeve, M. Z. P. Z., Sampson, J. R., and Kwiatkowski, D.

(2000). Molecular genetic advances in tuberous sclerosis. Hum. Genet. 107, 97-114.

74. Ito, N. and Rubin, G. M., (1999). gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell 96, 529-539.

75. Potter, C. J., Huang, H. E., and Xu, T. (2001). Drosophila TSC1 functions with TSC2 to antagonize insulin signaling in regulation cell growth, cell proliferation and organ size. Cell 105, 357-368.

76. Gao, X. and Pan, D. (2001). TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 15, 1383-1392.

77. Tapon, N., Ito, N., Dickson, B. J., Treisman, J. E., and Hariharan, I. K.

(2001). The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105, 345-355.

78. Kwiatkowski, D. J., Zhang, H., Bandura, J. L., Heiberger, K. M., Glogauer, M., el-Hashemite, N., and Onda, H. (2002). A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70 S6 kinase activity in TSC1 null cells. Human Mol. Genet. 11, 525-534.

79. Manning, B. D., Tee, A. R., Logsdon, M. M., Blenis, J., and Cantley, L. C. (2002). Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell 10, 151-162.

80. Avruch, J., Belham, C., Weng, Q., Hara, K., and Yonezawa, K. (2001).The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog. Mol. Subcell. Biol. 26, 115-154.

81. Alessi, D. R., Kozlowski, M. T., Weng, Q. P., Morrice, N., and Avruch, J.

(1998). 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr. Biol. 8, 69-81.

82. Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., and Thomas, G. (1998). Phosphorylation and activation of p70s6k by PDK. Science 279, 707-710.

83. Pearson, R. B., Dennis, P. B., Han, J. W., Williamson, N. A., Kozma, S. C., Wettenhall, R. E., and Thomas, G. (1995). The principal target of rapamycin-induced p70s6k inactivation is a novel phosphoryla-tion site within a conserved hydrophobic domain. EMBO J. 14, 5279-5287.

84. Balendran, A., Currie, R., Armstrong, C. G., Avruch, J., and Alessi, D. R.

(1999). Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252. J. Biol. Chem. 274, 37400-37406.

85. Williams, M. R., Arthur, J. S., Balendran, A., van der Kaay, J., Poli, V., Cohen, P., and Alessi, D. (2000). The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr. Biol. 10, 439-448.

86. Weng, Q. P., Kozlowski, M., Belham, C., Zhang, A., Comb, M. J., and Avruch, J. (1998). Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J. Biol. Chem. 273, 16621-16629.

87. Hara, K., Yonezawa, K., Weng, Q.-P., Kozlowski, M. T., Belham, C., and Avruch, J. (1998). Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 272, 14484-14494.

88. Peterson, R. T., Desai, B. N., Hardwick, J. S., and Schreiber, S. L. (1999). Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin associated protein. Proc. Natl. Acad. Sci. USA 96, 4438-4442.

89. Shalm, S. S. and Blenis, J. (2002). Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12, 632-539.

90. von Manteuffel, S. R, Dennis, P. B, Pullen, N., Gingras, A-C, Sonenberg, N., and Thomas, G. (1997). The insulin-induced signalling pathway leading to S6 and initiation factor4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol. Cell. Biol. 17, 5426-5436.

91. Di Como, C. J. and Arndt, K. T. (1996). Nutrients, via the TOR proteins stimulate the association of Tap42 with type 2A phosphatases. Genes Devel. 10, 1904-1916.

92. Jiang, Y. and Broach, J. R. (1999). TOR proteins and protein phos-phatase 2A reciprocally regulate Tap42 in controlling cell growth in yeast. EMBO J. 18, 2782-2792.

93. Jacinto, E., Guo, B., Arndt, K. T., Schmelze, T., and Hall M. N. (2001). TIP41 interacts with TAP42 and negatively regulates the TOR signaling pathway. Mol. Cell 5, 1017-1026.

94. Schmelzle, T. and Hall, M. N. (2000). TOR, a central controller of cell growth. Cell 103, 253-262.

95. Inui, S., Kuwahara, K., Mizutani J., Maeda, K., Kawai, T., Nakayasu, H., and Sakaguchi, N. (1995). Molecular cloning of a cDNA clone encoding a phosphoprotein component related to the Ig receptor-mediated signal transduction. J. Immunol. 154, 2714-2723.

96. Chen, J., Peterson, R. T., and Schreiber, S. L. (1998). Alpha 4 associates with protein phosphatases 2A, 4, and 6. Biochem. Biophys. Res. Commun. 247, 827-832.

97. Nanahoshi, M., Nishiuma, T., Tsujishita, Y., Hara, K., Inui, S., Sakaguchi, N., and Yonezawa, K. (1998). Regulation of protein phos-phatase 2A catalytic activity by alpha4 protein and its yeast homolog Tap42. Biochem. Biophys. Res. Commun. 251, 520-526.

98. Murata, K., Wu, J., and Brautigan, D. L. (1997). B cell receptor-associated protein a4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A. Proc. Natl. Acad. Sci. USA 94, 10624-10629.

99. Inui, S., Sanjo, H., Maeda, K., Yamamoto, H., Miyamoto, E., and Sakaguchi, N. (1998). Ig receptor binding protein 1 (alpha4) is associated with a rapamycin-sensitive signal transduction in lymphocytes through direct binding to the catalytic subunit of protein phosphatase 2A. Blood 92, 539-546.

100. Ziegler, W. H., Parekh, D. B., LeGood, J. A., Whelan, R. D. H., Kelly, J. J., Frech, M., Hemmings, B. A., and Parker, P. J. (1999). Rapamycin-sensitive phosphorylation of PKC on a carboxyterminal site by an atypical PKC complex. Curr. Biol. 9, 522-529.

101. Parekh, D., Ziegler, W., Yonezawa, K., Hara, K., and Parker, P. J. (1999). Mammalian TOR controls one of two kinase pathways acting upon nPKC □ and nPKC □. J. Biol. Chem. 274, 34758-34764.

102. Parekh, D. B., Ziegler, W., and Parker, P. J. (2000). Multiple pathways control protein kinase C phosphorylation. EMBO J. 19, 496-503.

103. Kumar, V., Pandey, P., Sabatini, D., Kumar, M., Majumder, P. K., Bharti, A., Carmichael, G., Kufe, D., and Kharbanda, S. (2000). Functional interaction between RAFT1/FRAP/mTOR and protein kinase C □ in the regulation of cap-dependent initiation of translation. EMBO J. 19, 1087-1097.

104. Scott, P. H. and Lawrence, Jr., J. C. (1998). A mammalian target of rapamycin activity by increased camp in 3T3-L1 adipocytes. J. Biol. Chem. 273, 34496-34501.

105. Scott, P. H., Brunn, G. J., Kohn, A. D., Roth, R. A., Lawrence, Jr., J. C. (1998). Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA 95, 7772-7777.

106. Sekulic, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., and Abraham, R. T. (2000). A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60, 3504-3513.

107. Yokoyami, K., Wakisaka, S., Avruch, J., and Reeves, S. A. (2002). Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol. 10, 47-50.

108. Takei, N., Kawamura, M., Hara, K., Yonezawa, K., and Nawa, H. (2001). Brain-derived neurotrophic factor enhances neuronal translation by activating multiple initiation processes: comparison with the effects of insulin. J. Biol. Chem. 276, 42818-42825.

109. Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., and Hay, N. (1998). 4E-BP1, a repressor of mRNA translation, is phos-phorylated and inactivated by the Akt (PKB) signaling pathway. Genes Devel. 12, 502-513.

110. Burgering, B. M. and Coffer, P. J. (1995). Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376, 599-602.

111. Nave, B. T., Ouwens, M., Withers, D. J., Alessi, D. R., and Shepherd, P. R. (1999). Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency of protein translation. Biochem. J. 344(pt. 2), 427-431.

112. Vilella-Bach, M., Nuzzi, P., Fang, Y., and Chen, J. (1999). The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J. Biol. Chem. 274, 4266-4272.

113. Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., and Chen, J. (2001). Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294, 1942-1945.

114. Sabatini, D. M., Barrow, R. K., Blackshaw, S., Burnett, P. E., Lai, M. M., Field, M. E., Bahr, B. A., Kirsch, J., Betz, H., and Snyder, S. H. (1999). Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling. Science 284, 1161-1164.

115. Fox, H. L., Kimball, S. R., Jefferson, L. S., and Lynch, C. J. (1998). Amino acids stimulate phosphorylation of p70S6k and organization of rat adipocytes into multicellular clusters. Am. J. Physiol. 274, C206-C213.

116. Patti, M. E., Brambilla, E., Luzi, L., Landaker, E. J., and Kahn, C R. (1998). Bidirectional modulation of insulin action by amino acids. J. Clin. Invest. 101, 1519-1529.

117. Wang, X., Campbell, L E., Miller, C. M., and Proud, C. G. (1998). Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem. J. 334, 261-267.

118. Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, Jr., J. C., and Abrahm, R. T. (1996). Direct inhibition of the signaling funcitons of the mammalian target of rapamycin by the phospho-inositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15, 5256-5267.

119. Lynch, C. J. (2001). Role of leucine in the regulation of mTOR by amino acids: revelations from structure-activity studies. J. Nutr. 131, 861-865.

120. Anthony, J. C., Anthony, T. G., Kimball, S. R., and Jefferson, L. S. (2001). Signaling pathways involved in translational control of protein synthesis in skeletal muscle by leucine. J. Nutr. 131, 856-860.

121. Kimball, S. R. and Jefferson, L. S. (2002). Control of protein synthesis by amino acid availability. Curr. Opin. Clin. Nutr. Metab. Care 5, 63-67.

122. Anthony, J. C., Lang, C. H., Crozier, S. J., Anthony, T. G., MacLean, D. A., Kimball, S. R., and Jefferson, L. S. (2002). Contribution of insulin to the translational control of protein synthesis in skeletal muscle by leucine. Am. J. Physiol. Endocrinol. 282, 1092-1101.

123. Anthony, J. C., Reiter, A. K., Anthony, T. G., Crozier, S. J., Lang, C. H., Maclean, D. A., Kimball, S. R., and Jefferson, L. S. (2000). Orally administered leucine enhances protein synthesis in skeletal muscle of diabetic rats in the absence of increases in 4E-BP1 or S6K1 phosphorylation. Diabetes 51, 928-936.

124. Mortimore, G. E., Wert, Jr., J. J., Miotto, G., Venerando, R., and Kadowaki, M. (1994). Leucine-specific binding of photoreactive Leu7-MAP to a high molecular weight protein on the plasma membrane of the isolated rat hepatocytes. Biochem. Biophys. Res. Commun. 203, 200-208.

125. Kardalinou, E., Zhelev, N., Hazzalin, C. A., and Mahadevan, L. C. (1994). Anisomycin and rapamycin define an area upstream of p70/85S6k containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction. Mol. Cell Biol. 14, 1066-1074.

126. Gressner, A. M. and Wool, I. G. (1974). The stimulation of the phosphorylation of ribosomal protein S6 by cycloheximide and puromycin. Biochem. Biophys. Res. Commun. 60, 1482-1490.

127. Khaleghpour, K., Pyronnet, S., Gingras, A.-C., and Sonenberg, N. (1999). Translational homeostasis: eukaryotic translation initiation factor 4E control of 4E-binding protein 1 and p70 S6 kinase activities. Mol. Cell Biol. 19, 4302-4310.

128. Chatterji, D. and Ojha, A. K. (2001). Revisiting the stringent response, ppGpp and starvation signaling. Curr. Opin. Microbiol. 4, 160-165.

129. Iiboshi, Y., Papst, P. J., Kawasome, H., Hosoi, H., Abraham, R. T., Houghton, P. J., and Terada, N. (1999). Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation. J. Biol. Chem. 274, 1092-1099.

130. Qui, H., Dong, J., Hu, C., Francklyn, C. S., and Hinnenbusch, A. G.

(2001). The tRNA-binding moiety in GCN2 contains a dimerization domain that interacts with the kinase domain and is required for tRNA binding and kinase activation. EMBO J. 20, 1425-2438.

131. Pollard, J. W., Lam, T., and Stanners, C. P. (1980). Mammalian cells do not have a stringent response. J. Cell Physiol. 105, 313-325.

132. Patel, J., Wang, X., and Proud, C. (2001). Glucose experts a permissive effect on the regulation of the initiation factor 4E binding 4E-BP1. Biochem. J. 358, 497-513.

133. Dennis, P. B., Jaeschke, A., Saitoh, M., Fowler, B., Kozama, S. C., and Thomas, G. (2001). Mammalian TOR: a homeostatic ATP sensor. Science 294, 1102-1105.

134. Hardie, D. G. and Hawley, S. A. (2001). AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 23, 1112-1119.

135. Kemp, B. E., Mitchelhill, K. I., Stapelton, D., Michael, B. J., Chen, Z. P., and Witters, L. A. (1999). Trends Biochem Sci. 24, 22-25.

136. Bolster, D. R, Crozier, S. J., Kimball, S. R., and Jefferson, L. S.

(2002). AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem. 277, 23977-23980.

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook

Post a comment